Literature DB >> 24329105

Histopathological analysis and clinical correlation of drug reaction with eosinophilia and systemic symptoms (DRESS).

M-H Chi1, R C-Y Hui, C-H Yang, J-Y Lin, Y-T Lin, H-C Ho, W-H Chung, T-T Kuo.   

Abstract

BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous adverse drug reaction. However, its histopathological features have not been well defined.
OBJECTIVES: To identify the clinicohistopathological findings of DRESS, and analyse the cutaneous histopathological changes observed in DRESS compared with those observed in maculopapular exanthema (MPE).
METHODS: In a retrospective study, conducted at Chang Gung Memorial Hospital (Taiwan) between 2001 and 2011, we compared the clinicohistopathological features of 32 patients with probable/definite DRESS (defined by the RegiSCAR scoring system) with those of 17 patients with MPE.
RESULTS: The major pathological changes observed in patients with DRESS included dyskeratosis (97%), epidermal spongiosis (78%), interface vacuolization (91%), perivascular lymphocytic infiltration (97%) and eosinophilic infiltration (72%). Many pathological features were common to both MPE and DRESS. However, severe dyskeratosis, epidermal spongiosis and severe interface vacuolization were significantly more prominent in cases of DRESS (P < 0·05). The presence of severe dyskeratosis was significantly associated with the clinical severity of renal impairment (P = 0·01).
CONCLUSIONS: The severe dyskeratosis detected in patients with DRESS may correlate with a greater extent of systemic involvement compared with that noted in MPE. However, the histopathological changes associated with DRESS are not entirely specific.
© 2013 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2014        PMID: 24329105     DOI: 10.1111/bjd.12783

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  13 in total

1.  Drug Reaction, Eosinophilia and Systemic Symptoms (DRESS) syndrome secondary to allopurinol with early lymphadenopathy and symptom relapse.

Authors:  Rhiannon Turney; Jordan Peter Skittrall; Joseph Donovan; Daniel Agranoff
Journal:  BMJ Case Rep       Date:  2015-10-05

2.  Drug rash with eosinophilia and systemic symptoms (DRESS) caused by phenytoin.

Authors:  Muhammad Riaz; Bruce D Ragsdale; Zia Ur Rahman; Gaurav Nigam
Journal:  BMJ Case Rep       Date:  2017-08-22

Review 3.  Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)-Readdressing the DReSS.

Authors:  Hannah Stirton; Neil H Shear; Roni P Dodiuk-Gad
Journal:  Biomedicines       Date:  2022-04-26

Review 4.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist.

Authors:  Marwan H Adwan
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.686

Review 5.  Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms.

Authors:  Ro-Lan Dao; Shih-Chi Su; Wen-Hung Chung
Journal:  Asia Pac Allergy       Date:  2015-04-29

Review 6.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System.

Authors:  Yung-Tsu Cho; Che-Wen Yang; Chia-Yu Chu
Journal:  Int J Mol Sci       Date:  2017-06-09       Impact factor: 5.923

Review 7.  Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions.

Authors:  Mari Orime
Journal:  J Immunol Res       Date:  2017-10-31       Impact factor: 4.818

8.  Severe Cutaneous Adverse Reaction (SCAR): Clinical Pharmacologists' Viewpoint.

Authors:  Nusrat Shafiq; Samiksha Bhattacharjee; Samir Malhotra
Journal:  Indian Dermatol Online J       Date:  2022-01-24

Review 9.  Eosinophils in skin diseases.

Authors:  Susanne Radonjic-Hoesli; Marie-Charlotte Brüggen; Laurence Feldmeyer; Hans-Uwe Simon; Dagmar Simon
Journal:  Semin Immunopathol       Date:  2021-06-07       Impact factor: 9.623

Review 10.  Recent Advances in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.

Authors:  Hideaki Watanabe
Journal:  J Immunol Res       Date:  2018-03-18       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.